Literature DB >> 3064217

AIDS-related lymphadenopathies.

J W Said1.   

Abstract

Lymphoid proliferations in the acquired immunodeficiency syndrome reflect the profound immunologic imbalances induced by the lymphotropic human immunodeficiency virus, and comprise a range of lymphoproliferative disorders from benign lymphadenopathy to malignant lymphoma. Persistent generalized lymphadenopathy (PGL) is associated with a frequently debilitating complex of clinical symptoms and waxing and waning lymphadenopathy. Biopsies of lymph nodes, bone marrow, and other involved tissues show a spectrum of abnormal lymphoid proliferations, with eventual lymphoid depletion, lymphadenopathic Kaposi's sarcoma, and malignant lymphoma. Although individual features of AIDS-related lymphadenopathy may not be specific, the constellation of histologic, immunologic, and ultrastructural findings is highly characteristic of the disorder and useful as a predictor of clinical course. Malignant lymphomas that develop within this setting of multicloncal B cell expansion and impaired immune surveillance have distinctive clinical, histologic, and molecular biologic parameters.

Entities:  

Mesh:

Year:  1988        PMID: 3064217

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  3 in total

Review 1.  The second century of the antibody. Molecular perspectives in regulation, pathophysiology, and therapeutic applications.

Authors:  J Braun; A Saxon; R Wall; S L Morrison
Journal:  West J Med       Date:  1992-08

Review 2.  Revenge of the microbes. Superantigens of the T and B cell lineage.

Authors:  L Goodglick; J Braun
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

3.  Localisation of HHV-8 in AIDS related lymphadenopathy.

Authors:  J J O'Leary; M Kennedy; K Luttich; V Uhlmann; I Silva; J Russell; O Sheils; M Ring; M Sweeney; C Kenny; N Bermingham; C Martin; M O'Donovan; D Howells; S Picton; S B Lucas
Journal:  Mol Pathol       Date:  2000-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.